Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Mouse (Murine) Antibodies:
anti-Rat (Rattus) Antibodies:
Go to our pre-filtered search.
Human Monoclonal NR1H4 Primary Antibody for IF, ELISA - ABIN523347
Chen, Song, Valanejad, Vasilenko, More, Qiu, Chen, Lai, Slitt, Stoner, Yan, Deng: Bile salt export pump is dysregulated with altered farnesoid X receptor isoform expression in patients with hepatocellular carcinoma. in Hepatology (Baltimore, Md.) 2013
Show all 2 Pubmed References
Human Polyclonal NR1H4 Primary Antibody for WB - ABIN4312873
Lian, Wang, Xiao, Wu, Xu, Liang, Yang: Activated farnesoid X receptor attenuates apoptosis and liver injury in autoimmune hepatitis. in Molecular medicine reports 2015
Human Polyclonal NR1H4 Primary Antibody for ELISA, WB - ABIN188692
Huang, Ma, Zhang, Qatanani, Cuvillier, Liu, Dong, Huang, Moore: Nuclear receptor-dependent bile acid signaling is required for normal liver regeneration. in Science (New York, N.Y.) 2006
Cow (Bovine) Polyclonal NR1H4 Primary Antibody for WB - ABIN2773865
Kaeding, Bouchaert, Bélanger, Caron, Chouinard, Verreault, Larouche, Pelletier, Staels, Bélanger, Barbier: Activators of the farnesoid X receptor negatively regulate androgen glucuronidation in human prostate cancer LNCAP cells. in The Biochemical journal 2008
Show all 2 Pubmed References
Human Polyclonal NR1H4 Primary Antibody for ICC, IF - ABIN152921
Xing, Saner-Amigh, Nakamura, Hinshelwood, Carr, Mason, Rainey: The farnesoid X receptor regulates transcription of 3beta-hydroxysteroid dehydrogenase type 2 in human adrenal cells. in Molecular and cellular endocrinology 2009
FXR regulates serum triglyceride level in part through PLA2G12B (show PLA2G12B Antibodies).
we conclude that FXR-Gank (show PSMD10 Antibodies)-TSPs-Stem cells pathway is a key determinant of liver cancer in animal models and in pediatric liver cancer. Our data provide a strong basis for development of FXR-Gank (show PSMD10 Antibodies)-based therapy for treatment of patients with hepatoblastoma
PPARalpha (show PPARA Antibodies) and FXR function coordinately to integrate liver energy balance.
These studies investigated in differentiated HepaRG cells and in primary human hepatocytes (PHHs) effects of FXR activation on HBV replication and of infection on the FXR pathway.
Treatment with LXR (show NR1H3 Antibodies) and FXR ligands initiates coated platelet formation, which is thought to support coagulation but results in desensitization to platelet stimuli through inhibition of alphaIIbbeta3 consistent with their ability to inhibit platelet function and stable thrombus formation in vivo.
FXR ligands to inhibit platelet activation.
Taken together, our data provide the first evidence that FXR suppresses proliferation of human liver cancer cells via the inhibition of the mTOR (show FRAP1 Antibodies)/S6K (show RPS6KB1 Antibodies) signaling pathway. FXR expression can be used as a biomarker of personalized mTOR (show FRAP1 Antibodies) inhibitor treatment assessment for liver cancer patients.
Activated FXR inhibits leptin (show LEP Antibodies) signaling and counteracts tumor-promoting activities of cancer-associated fibroblasts in breast malignancy.
FXR may promote the proliferation of tumor cells and the hepatocytes in the process of liver regeneration by activating the PDK4 (show PDK4 Antibodies)-mediated metabolic reprogramming to generate glycolytic intermediates essential for rapid biomass generation, establishing a mechanistic link between cell proliferation and metabolic switch.
this is the first report of bile acid derivatives able to antagonize GPBAR1 (show GPBAR1 Antibodies) and and farnesoid X receptor (show xpr1 Antibodies) (FXR) modulatory activity.
results suggest that hypothyroidism induces a moderate non-alcoholic steatohepatitis, alllowing the hepatic regeneration. The FXRalpha may be involved in the development of non-alcoholic steatohepatitis in hypothyroid subjects.
FXR is expressed in the ovary, in all regions of the oviduct, and all portions of the vagina of rabbits.
The study shows that FXR/RXR regulates Chop (show DDIT3 Antibodies) expression in a mouse model of steatohepatitis, providing novel insights into pathogenesis of this disorder.
FXR activation ameliorated central nervous system autoimmunity in an IL-10 (show IL10 Antibodies)-dependent fashion and even suppressed advanced clinical disease upon therapeutic administration
In livers of mice, FXR regulates amino acid catabolism and detoxification of ammonium via ureagenesis and glutamine (show GFPT1 Antibodies) synthesis.
Data suggest that FXR and TGR5 (show GPBAR1 Antibodies) expression is down-regulated in aging kidney; caloric restriction prevents these age-related changes. Additionally, in long-lived Ames dwarf (show PROP1 Antibodies) mice, renal FXR and TGR5 (show GPBAR1 Antibodies) expression is up-regulated. Treatment of aged mice with dual FXR/TGR5 (show GPBAR1 Antibodies) agonist reverses age-related changes in kidney structure/function. (FXR = farnesoid X activated receptor; TGR5 (show GPBAR1 Antibodies) = G protein-coupled bile acid receptor 1 (show GPBAR1 Antibodies))
this study provides evidence for roles of FXR as an important regulator of placental inflammation
These findings suggest that bile acids and FXR play pivotal roles in sepsis via controlling the NLRP3 (show NLRP3 Antibodies) inflammasome.
Our results indicate that the gut (show GUSB Antibodies) microbiota promotes diet-induced obesity and associated phenotypes through FXR, and that FXR may contribute to increased adiposity by altering the microbiota composition.
findings uncovered a novel mechanism in which INT-767 activation of FXR induces Tgr5 (show GPBAR1 Antibodies) gene expression and increases Ca(2 (show CA2 Antibodies)+) levels and cAMP activity to stimulate GLP-1 (show GCG Antibodies) secretion and improve hepatic glucose and lipid metabolism in high-fat diet-induced obese mice.
In mice, we found transintestinal cholesterol excretion to be regulated by intestinal FXR via induction of its target gene Fgf15.
alterations in bile acid composition may have contributed to the observed disturbance in FXR-mediated signalling pathways in short bowel syndrome-associated liver disease
FXR splice variant has a dominant positive effect on wild type FXR.
In conclusion, PXR (show NR1I2 Antibodies) and FXR both responded to ligands that activated their human orthologs, and some of the alternatively spliced variants significantly altered PXR (show NR1I2 Antibodies) and FXR transactivation at in vivo expression levels.
This gene encodes a ligand-activated transcription factor, which shares structural features in common with nuclear hormone receptor family, such as a DNA-binding domain that targets the receptor to specific DNA sequences, and a ligand-binding domain, which interacts directly with the ligand and contains a ligand-dependent transcriptional activation domain. This protein functions as a receptor for bile acids, and when bound to bile acids, regulates the expression of genes involved in bile acid synthesis and transport. Alternatively spliced transcript variants encoding different isoforms have been described for this gene.
nuclear receptor subfamily 1, group H, member 4
, orphan nuclear receptor FOR2
, bile acid receptor
, farnesoid X activated receptor
, bile acid receptor-like
, RXR-interacting protein 14
, farnesoid X nuclear receptor
, farnesoid X-activated receptor
, farnesol receptor HRR-1
, retinoid X receptor-interacting protein 14
, nuclear receptor subfamily 1 group H member 4